Sanofi to expand immunology offerings with Blueprint Medicines
Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.
Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.
What's Your Reaction?
